Search for drugs:

PITAVASTATIN CALCIUM


DIR Classification


Classification:Ambiguous
Severity Score:1.0

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

  • CLINICAL PHARMACOLOGY
  • Pharmacodynamics
  • Cardiac Electrophysiology
  • In a randomized, double-blind, placebo-controlled, 4-way parallel, active-comparator study with moxifloxacin in 174 healthy participants, LIVALO was not associated with clinically meaningful prolongation of the QTc interval or heart rate at daily doses up to 16 mg (4 times the recommended maximum dose of 4 mg daily).

Postmarketing Surveillance

Contingency Table:

Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
4524
38377063

Odds Ratio = 0.0

Drug Property Information



ATC Code(s):
  • C10AA08 - pitavastatin calcium
    • C10AA0 -
    • C10AA - HMG CoA reductase inhibitors
    • C10A - "LIPID MODIFYING AGENTS, PLAIN"
    • C10 - LIPID MODIFYING AGENTS
    • C - CARDIOVASCULAR SYSTEM
Active Ingredient:pitavastatin calcium
Active Ingredient UNII:IYD54XEG3W
Drugbank ID:DB08860
PubChem Compound:5282452
CTD ID:C108475
PharmGKB:PA142650384
CAS Number:147511-69-1
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
  • 2.0 mg/day C10AA08
Chemical Structure:
SMILE Code:
O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O

Reference

N/A

Disclaimer:

The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.

Any mention of commercial products is for clarification and not intended as endorsement.